Form 144 Filer Information

FORM 144

Filer CIK

144: Filer Information

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

0001966926

Filer CCC	XXXXXXX
Is this a LIVE or TEST Filing?	● LIVE ◎ TEST
Submission Contact Information	
Name	
Phone	
E-Mail Address	
144: Issuer Information	
Name of Issuer	Atara Biotherapeutics, Inc.
SEC File Number	001-36548
Address of Issuer	c/o Atara Biotherapeutics, Inc. 2380 Conejo Spectrum St., Suite 200 Thousand Oaks CALIFORNIA 91320
Phone	805-623-4211
Name of Person for Whose Account the Securities are To Be Sold	Hyllengren Eric J
the securities are to be sold but also as to a	(a) of Rule 144. Information is to be given not only as to the person for whose account all other persons included in that definition. In addition, information shall be given as to ired by paragraph (e) of Rule 144 to be aggregated with sales for the account of the
Relationship to Issuer	Officer
144: Securities Information	on
Title of the Class of Securities To Be Sold	Common Stock
Name and Address of the Broker	Morgan Stanley Smith Barney LLC Executive Services 200 W Civic Center Drive, 4th Floor Sandy UT 84070
Number of Shares or Other Units To Be Sold	6655
Aggregate Market Value	5129.01
Number of Shares or Other Units Outstanding	101922250
Approximate Date of Sale	03/04/2024
Name the Securities Exchange	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold	
Title of the Class	Common Stock
Date you Acquired	03/01/2024
Nature of Acquisition Transaction	Settlement of vested RSUs issued under an S-8 Registration Plan
Name of Person from Whom Acquired	Issuer
Is this a Gift?	Date Donor Acquired
Amount of Securities Acquired	14141
Date of Payment	03/01/2024
Nature of Payment	Equity compensation for services rendered

note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement. Exhibit List: Exhibit 24 - Power of Attorney.

Date of Notice

03/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Jeff Kiekhofer, Attorney-in-Fact for Eric J. Hyllengren

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

POWER OF ATTORNEY

Know all by these present, that the undersigned, as a Section 16 reporting person of Atara Biotherapeutics, Inc. (the "Company"), hereby constitutes and appoints each of Amar Murugan, Jeff Kiekhofer and John Chao, or either of them acting individually, and with full power of substitution, the undersigned's true and lawful attorneys-in-fact to:

- 1. Complete and execute Forms 3, 4 and 5, Forms 144, and other forms and all amendments thereto, as such attorneys-in-fact shall in their discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, Rule 144 under the Securities Act of 1933 ("Rule 144"), or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 2. Do and perform any and all acts on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, or Form 144 with the Securities and Exchange Commission (the "SEC"), any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended) or Rule 144.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5, and Forms 144 with the SEC with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of February 21, 2024.

Signature: /s/ Eric Hyllengren	
	Eric Hyllengren